Literature DB >> 12871844

Comparative regional haemodynamic effects of the nitric oxide synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats.

Ian D Wakefield1, Julie E March, Philip A Kemp, Jean-Pierre Valentin, Terence Bennett, Sheila M Gardiner.   

Abstract

1. The regional haemodynamic effects of the putative nNOS inhibitor, S-methyl-L-thiocitrulline (SMTC), were compared with those of the nonselective NOS inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), in conscious, male Sprague-Dawley rats. 2. SMTC (0.3 mg kg(-1) bolus) produced a significant, short-lived, pressor effect associated with renal, mesenteric and hindquarters vasoconstriction; the same dose of L-NAME did not affect mean blood pressure (BP), although it caused bradycardia and mesenteric vasoconstriction. 3. At the highest dose tested (10 mg kg(-1)), L-NAME produced a significantly greater bradycardia and fall in mesenteric vascular conductance than SMTC, although the initial pressor response to SMTC was greater, but less sustained, than that to L-NAME. 4. Infusion of SMTC or L-NAME (3 mg kg(-1) h(-1)) induced rises in BP and falls in renal, mesenteric and hindquarters vascular conductances, but the effects of L-NAME were greater than those of SMTC, and L-NAME also caused bradycardia. 5. The renal vasodilator response to acetylcholine was markedly attenuated by infusion of L-NAME, but unaffected by SMTC. The hindquarters vasodilatation induced by salbutamol was attenuated by L-NAME, but not by SMTC. The mesenteric vasodilator response to bradykinin was modestly enhanced by SMTC, but not by L-NAME. The depressor and renal, mesenteric and hindquarters vasodilator responses to sodium nitroprusside were enhanced by L-NAME, whereas SMTC modestly enhanced the hypotensive and renal vasodilator effects of sodium nitroprusside, but attenuated the accompanying tachycardia. 6. The results are consistent with the cardiovascular effects of low doses of SMTC being attributable to nNOS inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871844      PMCID: PMC1573945          DOI: 10.1038/sj.bjp.0705351

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Stimulation of lumbar sympathetic nerves may produce hindlimb vasodilation via the release of pre-formed stores of nitrosyl factors.

Authors:  R L Davisson; R A Shaffer; A K Johnson; S J Lewis
Journal:  Neuroscience       Date:  1996-06       Impact factor: 3.590

Review 2.  Nitroxidergic nerve: regulation of vascular tone and blood flow in the brain.

Authors:  N Toda; T Okamura
Journal:  J Hypertens       Date:  1996-04       Impact factor: 4.844

3.  Local NADPH-diaphorase neurons innervate pial arteries and lie close or project to intracerebral blood vessels: a possible role for nitric oxide in the regulation of cerebral blood flow.

Authors:  C Estrada; E Mengual; C González
Journal:  J Cereb Blood Flow Metab       Date:  1993-11       Impact factor: 6.200

4.  Evidence from its cardiovascular effects that 7-nitroindazole may inhibit endothelial nitric oxide synthase in vivo.

Authors:  Y Zagvazdin; G Sancesario; Y X Wang; L Share; M E Fitzgerald; A Reiner
Journal:  Eur J Pharmacol       Date:  1996-05-06       Impact factor: 4.432

5.  Effect of nitric oxide synthase inhibition on cardiorespiratory responses in the conscious rat.

Authors:  D Gozal; J E Torres; Y M Gozal; S M Littwin
Journal:  J Appl Physiol (1985)       Date:  1996-11

6.  Effects of chronic treatment with nitric oxide synthase inhibitors on regional haemodynamic responses to vasodilators in conscious Brattleboro rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

7.  Stretch revealed three components in the hyperpolarization of guinea-pig coronary artery in response to acetylcholine.

Authors:  H C Parkington; M Tare; M A Tonta; H A Coleman
Journal:  J Physiol       Date:  1993-06       Impact factor: 5.182

8.  Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine.

Authors:  S Pfeiffer; E Leopold; K Schmidt; F Brunner; B Mayer
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  S-alkyl-L-thiocitrullines. Potent stereoselective inhibitors of nitric oxide synthase with strong pressor activity in vivo.

Authors:  K Narayanan; L Spack; K McMillan; R G Kilbourn; M A Hayward; B S Masters; O W Griffith
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

10.  Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline.

Authors:  E S Furfine; M F Harmon; J E Paith; R G Knowles; M Salter; R J Kiff; C Duffy; R Hazelwood; J A Oplinger; E P Garvey
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

View more
  17 in total

1.  Effects of neuronal nitric oxide synthase inhibition on resting and exercising hindlimb muscle blood flow in the rat.

Authors:  Steven W Copp; Daniel M Hirai; Peter J Schwagerl; Timothy I Musch; David C Poole
Journal:  J Physiol       Date:  2010-02-22       Impact factor: 5.182

2.  Hypotestosteronemia is an important factor for the development of hypertension: elevated blood pressure in orchidectomized conscious rats is reversed by different androgens.

Authors:  Mercedes Perusquía; Daniela Contreras; Nieves Herrera
Journal:  Endocrine       Date:  2019-06-15       Impact factor: 3.633

3.  Neuronal nitric oxide synthase regulation of skeletal muscle functional hyperemia: exercise training and moderate compensated heart failure.

Authors:  Daniel M Hirai; Steven W Copp; Scott K Ferguson; Clark T Holdsworth; K Sue Hageman; David C Poole; Timothy I Musch
Journal:  Nitric Oxide       Date:  2017-12-27       Impact factor: 4.427

4.  Effects of chronic heart failure on neuronal nitric oxide synthase-mediated control of microvascular O2 pressure in contracting rat skeletal muscle.

Authors:  Steven W Copp; Daniel M Hirai; Scott K Ferguson; Clark T Holdsworth; Timothy I Musch; David C Poole
Journal:  J Physiol       Date:  2012-06-11       Impact factor: 5.182

5.  Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response.

Authors:  Sheila M Gardiner; Julie E March; Philip A Kemp; Terence Bennett
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

6.  Neuronal nitric oxide synthase inhibition and regional sympathetic nerve discharge: implications for peripheral vascular control.

Authors:  Steven W Copp; Daniel M Hirai; Gabrielle E Sims; Richard J Fels; Timothy I Musch; David C Poole; Michael J Kenney
Journal:  Respir Physiol Neurobiol       Date:  2013-02-27       Impact factor: 1.931

7.  Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat.

Authors:  Yan Li; Xizhong Cui; Wanying Xu; Lernik Ohanjanian; Hanish Sampath-Kumar; Dante Suffredini; Mahtab Moayeri; Stephen Leppla; Yvonne Fitz; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-22       Impact factor: 4.733

8.  Nitric oxide originating from NOS1 controls oxygen utilization and electrolyte transport efficiency in the diabetic kidney.

Authors:  Fredrik Palm; Angelica Fasching; Peter Hansell; Orjan Källskog
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18

9.  Effects of neuronal nitric oxide synthase inhibition on microvascular and contractile function in skeletal muscle of aged rats.

Authors:  Daniel M Hirai; Steven W Copp; Clark T Holdsworth; Scott K Ferguson; Timothy I Musch; David C Poole
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-24       Impact factor: 4.733

10.  Administration of S-methyl-L-thiocitrulline protects against brain injuries after intracerebral hemorrhage.

Authors:  A Lu; K R Wagner; J P Broderick; J F Clark
Journal:  Neuroscience       Date:  2014-04-13       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.